Syndax Pharmaceuticals Inc (SNDX NASDAQ) stock market data APIs
$9.3852
0.33(3.5%)
as of November 13, 2026
Try our APIs with
free plan!
Syndax Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Prev. Close
9.3852
Open
9.7106
High
9.8505
Low
9.1917
52 wk Range
9.11-25.59
Market Cap
851 M
Shares Outstanding
90 028 K
Revenue
290 M
EPS
-0.55
Beta
0.45
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Syndax Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Syndax Pharmaceuticals Inc data using free add-ons & libraries
Get Syndax Pharmaceuticals Inc Fundamental Data
Syndax Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 290 M
- EBITDA: -178 622 000
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Syndax Pharmaceuticals Inc Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-11-02
- EPS/Forecast: -0.52
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Syndax Pharmaceuticals Inc News
New
Syndax anticipates Revuforj could exceed $2B in U.S. peak annual net revenue as post-transplant maintenance builds
Earnings Call Insights: Syndax Pharmaceuticals (SNDX) Q3 2026 MANAGEMENT VIEW * “Syndax delivered another strong quarter of commercial growth and pipeline momentum. Total revenue reached $83 mil...
Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
The market expects Syndax Pharmaceuticals (SNDX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known con...
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal
Syndax Pharmaceuticals SNDX shares fell 15.7% on Tuesday after the company reported that its mid-stage study of axatilimab in idiopathic pulmonary fibrosis (IPF) failed to meet the primary endpoint. T...
Top Midday Decliners
UBS downgraded Acadia Pharmaceuticals' (ACAD) shares one notch to neutral and set a $23 price target PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Get Syndax Pharmaceuticals Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.